For example, miRNA-21 [26] and miRNA-139-3p [27] involved in the aggressiveness of NSCLC, miRNA-130a was reported to promote the cisplatin resistance and promote the progression of NSCLC via inhibiting PUM-2 expression [28]. The gene discussed is PUM2; the disease is non-small cell lung carcinoma.